The rapidly evolving research on vitamin D among HIV-infected populations

被引：25

作者：

Overton E.T. ^{[1
]}

Yin M.T. ^{[2
]}

机构：

[1] Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110

[2] Division of Infectious Diseases, Columbia University Medical Center, New York, NY, PH8-876

来源：

Current Infectious Disease Reports | 2011年 / 13卷 / 1期

关键词：

AIDS; Bone health; HIV; Vitamin D;

D O I：

10.1007/s11908-010-0144-x

中图分类号：

学科分类号：

摘要：

With ongoing improvement in antiretroviral therapy, mortality among HIV-infected persons has dramatically decreased. For HIV-infected persons who remain engaged in care on suppressive therapy, life expectancy approaches that of the general population. Additionally, we have seen increases in comorbidities traditionally associated with aging: diabetes, hypertension, dyslipidemia, ischemic heart disease, and osteoporosis. Vitamin D deficiency has also been identified as a highly prevalent entity among HIV-infected populations. The association of vitamin D deficiency with several of these comorbidities and its impact on immune function provide the impetus for well-designed studies to evaluate the impact of vitamin D supplementation on HIV disease and antiretroviral therapy. This review summarizes the role of vitamin D in several disease states that are prevalent among HIV populations, with a specific focus on bone health and the interactions with antiretroviral medications. © 2010 Springer Science+Business Media, LLC.

引用

页码：83 / 93

页数：10

共 115 条

[1]

Palella Jr. F.J., Baker R.K., Moorman A.C., Chmiel J.S., Wood K.C., Brooks J.T., Holmberg S.D., Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study, Journal of Acquired Immune Deficiency Syndromes, 43, 1, pp. 27-34, (2006)

[2]

Lampe F.C., Smith C.J., Madge S., Kinloch-de Loes S., Tyrer M., Sabin C.A., Chaloner C., Youle M., Johnson M.A., Phillips A.N., Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004, Archives of Internal Medicine, 167, 7, pp. 692-700, (2007)

[3]

Bhavan K.P., Kampalath V.N., Overton E.T., The aging of the HIV epidemic, Curr HIV/AIDS Rep., 5, 3, pp. 150-158, (2008)

[4]

Tebas P., Powderly W.G., Claxton S., Marin D., Tantisiriwat W., Teitelbaum S.L., Yarasheski K.E., Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy, AIDS, 14, 4, (2000)

[5]

Brown T.T., Qaqish R.B., Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review, AIDS, 20, 17, pp. 2165-2174, (2006)

[6]

Triant V.A., Brown T.T., Lee H., Grinspoon S.K., Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system, J Clin Endocrinol Metab, 93, 9, pp. 3499-3504, (2008)

[7]

McComsey G.A., Tebas P., Shane E., Et al., Bone Disease in HIV: A Practical Review and Recommendations for HIV Providers, CID, 51, pp. 937-946, (2010)

[8]

Hess A.F., Unger L.F., The cure of infantile rickets by sunlight, JAMA, 77, 1, pp. 39-41, (1921)

[9]

Chalmers J., Conacher W.D.H., Garnder D.L., Scott P.J., Osteomalacia: A common disease in elderly women, J Bone Joint Surg Br., 49, 3, pp. 403-423, (1967)

[10]

Holick M.F., Medical progress: Vitamin D deficiency, New England Journal of Medicine, 357, 3, pp. 266-281, (2007)

← 1 2 3 4 5 6 7 8 9 10 →